drugset / Trial / NCT00280631
Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and efficacy of TLK199 Tablets in patients with Myelodysplastic Syndrome (MDS)
Timeline
- Start
- 2006-02
- Primary completion
- 2008-03
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ezatiostat | Small molecule | 200 mg | Oral |
| Subject | ezatiostat | Small molecule | 400 mg | Oral |
| Subject | ezatiostat | Small molecule | 1000 mg | Oral |
| Subject | ezatiostat | Small molecule | 1400 mg | Oral |
| Subject | ezatiostat | Small molecule | 2000 mg | Oral |
| Subject | ezatiostat | Small molecule | 2400 mg | Oral |
| Subject | ezatiostat | Small molecule | 3000 mg | Oral |
| Subject | ezatiostat | Small molecule | 4000 mg | Oral |
| Subject | ezatiostat | Small molecule | 5000 mg | Oral |
| Subject | ezatiostat | Small molecule | 6000 mg | Oral |